Influenza A virus vaccine H3N2 - sanofi pasteur

Drug Profile

Influenza A virus vaccine H3N2 - sanofi pasteur

Alternative Names: H3N2v vaccine - sanofi pasteur; Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203 vaccine - sanofi pasteur; Monovalent inactivated influenza H3N2 variant vaccine - sanofi pasteur

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator sanofi pasteur
  • Developer National Institute of Allergy and Infectious Diseases; Sanofi Pasteur
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H3N2 subtype

Most Recent Events

  • 23 Mar 2017 Phase-II development for Influenza-A virus H3N2 subtype (Prevention) is ongoing in USA (IM)
  • 29 Sep 2016 National Institute of Allergy and Infectious Diseases plans a phase II trial for Influenza-A virus H3N2 subtype (Prevention, In adults) in USA (IM) (NCT02921997)
  • 21 May 2014 NIAID plans a phase II trial for Influenza-A virus H3N2 subtype (prevention in infants, children and adolescents) in USA (NCT02100436)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top